China special issue on gastrointestinal tumor: Regulatory-immunoscore-A novel indicator to guide precision adjuvant chemotherapy in colorectal cancer

Novel biomarkers are essential to improve the treatment efficacy and overall survival of stage II and III colorectal cancer (CRC), allowing for personalized treatment decisions. Here, the densities of CD8 and FOXP3 T cells in the tumor and invasive margin were processed by immunohistochemistry and d...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2023-12
Main Authors: Fang, Lin, Yao, Yang, Guan, Xin, Liao, Yuanyu, Wang, Bojun, Cui, Luying, Han, Shuling, Zou, Haoyi, Su, Dan, Ma, Yue, Liu, Biao, Wang, Yao, Huang, Rui, Ruan, Yuli, Yu, Xuefan, Yao, Yuanfei, Liu, Chao, Zhang, Yanqiao
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Novel biomarkers are essential to improve the treatment efficacy and overall survival of stage II and III colorectal cancer (CRC), allowing for personalized treatment decisions. Here, the densities of CD8 and FOXP3 T cells in the tumor and invasive margin were processed by immunohistochemistry and digital pathology to form a scoring system named regulatory-Immunoscore (RIS). Cox proportional hazards regression models were used to determine the risk factors associated with time to recurrence. Harrell's concordance index and the time-dependent area under the curve were used to assess model performance. A total of 1213 stage I-III DNA mismatch repair-proficient colorectal cancer (pMMR CRC) patients were randomly assigned to a training set (n = 642) and a validation set (n = 571). From the Cox multivariable analysis, the association of RIS with survival was independent of patient age, sex and anatomy-based tumor risk parameters (P 
ISSN:1097-0215
DOI:10.1002/ijc.34539